Recombinant Adenoviral Gene Transfer Does Not Affect Cardiac Allograft Vasculopathy

Journal of Heart and Lung Transplantation

Volumn 26, Issue 12, 2007, Pages 1281-1285

  Rao, Vinay P ^a   Branzoli, Stefano E ^a   Ricci, Davide ^a,b   Miyagi, Naoto ^a   O'Brien, Timothy ^a   Tazelaar, Henry D ^a   Russell, Stephen J ^a   McGregor, Christopher G A ^a  

^a Mayo Clinic College of Medicine   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CYCLOSPORIN; EOSIN; HEMATOXYLIN; UNIVERSITY OF WISCONSIN SOLUTION;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN NORWAY RAT; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; EX VIVO GENE TRANSFER; LEWIS RAT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CYCLOSPORINE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; RANDOM ALLOCATION; RATS; RATS, INBRED BN; RATS, INBRED LEW; TIME FACTORS; VASCULAR DISEASES;

EID: 37149013992     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.09.018     Document Type: Article

References (32)

1. Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?. Curr Control Trials Cardiovasc Med 1 (2000) 166-171
2. Valantine H.A. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 4 (2004) 169-177
3. Shirali G.S., Ni J., Chinnock R.E., et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 344 (2001) 1498-1503
4. Ivan D., Frazier O.H., and Abrams J. Fatal disseminated adenoviral infection in an adult heart transplant patient. J Heart Lung Transplant 23 (2004) 1209-1212
5. Avery R.K. Viral triggers of cardiac-allograft dysfunction. N Engl J Med 344 (2001) 1545-1547
6. Hattori T., Shimokawa H., Higashi M., et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 94 (2004) 46-52
7. Sata M., Luo Z., and Walsh K. Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J Immunol 166 (2001) 6964-6971
8. Longo C.R., Arvelo M.B., Patel V.I., et al. A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Circulation 108 (2003) 1113-1118
9. Sun H., Subbotin V., Chen C., et al. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. Transplantation 64 (1997) 1838-1843
10. Brauner R., Wu L., Laks H., et al. Intracoronary gene transfer of immunosuppressive cytokines to cardiac allografts: method and efficacy of adenovirus-mediated transduction. J Thorac Cardiovasc Surg 113 (1997) 1059-1067
11. Li J., Simeoni E., Fleury S., et al. Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model. Eur J Cardiothorac Surg 29 (2006) 779-783
12. Ye L., Haider H., Jiang S., Ge R., Law P.K., and Sim E.K. In vitro functional assessment of human skeletal myoblasts after transduction with adenoviral bicistronic vector carrying human VEGF165 and angiopoietin-1. J Heart Lung Transplant 24 (2005) 1393-1402
13. Muruve D.A. The innate immune response to adenovirus vectors. Hum Gene Ther 15 (2004) 1157-1166
14. Bessis N., Garcia Cozar F.J., and Boissier M.C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11 suppl 1 (2004) S10-S17
15. Newman K.D., Dunn P.F., Owens J.W., et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 96 (1995) 2955-2965
16. Zhang H.G., Zhou T., Yang P., Edwards III C.K., Curiel D.T., and Mountz J.D. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther 9 (1998) 1875-1884
17. Pellegrini C., Jeppsson A., Taner C.B., et al. Highly efficient ex vivo gene transfer to the transplanted heart by means of hypothermic perfusion with a low dose of adenoviral vector. J Thorac Cardiovasc Surg 119 (2000) 493-500
18. Ono K., and Lindsey E.S. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 57 (1969) 225-229
19. Kawauchi M., Suzuki J., Morishita R., et al. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res 87 (2000) 1063-1068
20. Aranda Jr. J.M., and Hill J. Cardiac transplant vasculopathy. Chest 118 (2000) 1792-1800
21. Vassalli G., Gallino A., Weis M., et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 24 (2003) 1180-1188
22. Weis M., and von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 96 (1997) 2069-2077
23. Chen D., Ding Y., Schroppel B., et al. Differential chemokine and chemokine receptor gene induction by ischemia, alloantigen, and gene transfer in cardiac grafts. Am J Transplant 3 (2003) 1216-1229
24. Yap J., Pellegrini C., O'Brien T., Tazelaar H.D., and McGregor C.G. Conditions of vector delivery improve efficiency of adenoviral-mediated gene transfer to the transplanted heart. Eur J Cardiothorac Surg 19 (2001) 702-707
25. Pellegrini C., O'Brien T., Yap J., Jeppsson A., Tazelaar H.D., and McGregor C.G. Systematic evaluation of distribution of transgene expression after adenovirus-mediated gene transfer to the transplanted heart. Transplant Int 11 (1998) 373-377
26. Chan S.Y., Li K., Piccotti J.R., et al. Tissue-specific consequences of the anti-adenoviral immune response: implications for cardiac transplants. Nat Med 5 (1999) 1143-1149
27. Johnson P., Carpenter M., Hirsch G., and Lee T. Recipient cells form the intimal proliferative lesion in the rat aortic model of allograft arteriosclerosis. Am J Transplant 2 (2002) 207-214
28. Seipelt I.M., Pahl E., Seipelt R.G., et al. Neointimal inflammation and adventitial angiogenesis correlate with severity of cardiac allograft vasculopathy in pediatric recipients. J Heart Lung Transplant 24 (2005) 1039-1045
29. Abunasra H., Smolenski R.T., Yap J., et al. Comparison of two gene transfer models for the attenuation of myocardial ischemia-reperfusion injury following preservation for cardiac transplantation. Eur J Cardiothorac Surg 29 (2006) 772-778
30. Abunasra H.J., Smolenski R.T., Yap J., et al. Multigene adenoviral therapy for the attenuation of ischemia-reperfusion injury after preservation for cardiac transplantation. J Thorac Cardiovasc Surg 125 (2003) 998-1006
31. Oi K., Davies W.R., Tazelaar H.D., et al. Ex vivo hypothermic recirculatory adenoviral gene transfer to the transplanted pig heart. J Gene Med 8 (2006) 795-803
32. Kitagawa-Sakakida S., Fukushima N., Sawa Y., et al. Microarray-based gene expression profiling of retransplanted rat cardiac allografts that develop cardiac allograft vasculopathy. J Heart Lung Transplant 24 (2005) 2068-2074